Inherited colorectal cancer syndromes

Cancer Journal

Volumn 17, Issue 6, 2011, Pages 405-415

  Kastrinos, Fay ^a   Syngal, Sapna ^b,c,d  

^a NewYork Presbyterian Hospital   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Inherited colorectal cancer syndromes

Indexed keywords

ADENOMATOUS POLYP; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CLINICAL FEATURE; COWDEN SYNDROME; GENE MUTATION; GENETIC ANALYSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; MULTIPLE CANCER; MYH GENE; ONCOGENE; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; RARE DISEASE; REVIEW; UNITED STATES;

COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 83755174149     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318237e408     Document Type: Review

References (72)

1. Siegel R,Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Burt RW. Colon cancer screening. Gastroenterology. 2000;119: 837-853.
3. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer. N Engl J Med. 2000; 343:78-85.
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919-932. (Pubitemid 36298000)
5. Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology. 2003;124:1574-1594. (Pubitemid 36617678)
6. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetic and clinical implications. Ann Intern Med. 2003;138: 560-570.
7. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829-834. (Pubitemid 30243745)
8. de Jong AE, Hendiks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006;130:665-671. (Pubitemid 43374516)
9. Heiskanen I, Luostarinen T, Jarvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol. 2000;35:1284-1287. (Pubitemid 32051643)
10. Lynch HT, Shaw MW, Magnuson CW, et al. Hereditary factors in cancer: study of two large midwestern kindreds. Arch Intern Med. 1966;117: 106-112.
11. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137:1621-1627.
12. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64:430-433. (Pubitemid 26048907)
13. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in Lynch syndrome. JAMA. 2009;302:1790-1795.
14. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079-1099.
15. Nyström-Lahti M, Wu Y, Moisio AL, et al. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary nonpolyposis colorectal cancer. Hum Mol Genet. 1996;5:763-769. (Pubitemid 26171291)
16. Moslein G, Tester DJ, Lindor NM, et al. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet. 1996;5: 1245-1252. (Pubitemid 26335841)
17. Wijnen J, Khan PM, Vasen H, et al. Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet. 1997;61:329-335. (Pubitemid 27382308)
18. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801-818. (Pubitemid 29520569)
19. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes: second edition. J Natl Cancer Inst Monogr. 2008;308:1-93.
20. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268. (Pubitemid 38256271)
21. Green RC, Parfrey PS, Woods MO, et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009;101:331-340.
22. Pouchet CJ, Wong N, Chong G, et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann Oncol. 2009;20: 681-688.
23. Monzon JG, Cremin C, Armstrong L, et al. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int J Cancer. 2010;126:930-939.
24. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch repair genes in colon cancers. N Engl J Med. 2006;354:2751-2763. (Pubitemid 43974193)
25. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296:1479-1487. (Pubitemid 44465512)
26. Kastrinos F, Steyerberg E, Mercado R, et al. The PREMM1,2,6 model predicts risk of germline MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140:73-81.
27. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and costeffectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res. 2011;4:9-22.
28. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.
29. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet. 1999;65: 1291-1298. (Pubitemid 30460379)
30. Kastrinos F, Steyerberg EW, Balmana J, et al. Comparison of the clinical prediction model PREMM1,2,6 with colorectal cancer molecular tumor testing for Lynch syndrome in the Colon Cancer Family Registry. Gastroenterology. 2010;138:A1028.
31. American Society for Clinical Oncology. American Society for Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
32. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979-1985. (Pubitemid 40570891)
33. Kempers MJ, Kuiper RP, Ockeleon CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletionYpositive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12:49-55.
34. Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044-2058.
35. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507-1517. (Pubitemid 44465515)
36. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecological cancers in Lynch syndrome. N Engl J Med. 2006;354:261-169.
37. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis. Gastroenterology. 1991;1000:1658-1671.
38. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101:385-398. (Pubitemid 43381685)
39. Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. The DAF Study Group. Gut. 2004;53: 381-386. (Pubitemid 38241334)
40. Vasen HFA, Bulow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut. 1997;40:716-719. (Pubitemid 27305462)
41. Heiskanen I, Jarvinen HJ. Occurrence of desmoids tumours in familial adenomatous polyposis and results of treatment. Int J Colorect Dis. 1996;11:157-162. (Pubitemid 26275832)
42. Traboulsi EI, Krush AJ, Gardner EJ, et al. Prevalence and importance of pigmented ocular fundus lesions in Gardner's syndrome. N Engl J Med. 1987;316:661-667. (Pubitemid 17032951)
43. Knudsen AL, Bisgaard ML, Burlow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2: 43-55. (Pubitemid 36534538)
44. Burt RW, Jacoby RF. Polyposis syndromes. Textbook of Gastroenterology. Volume 2. 4th ed. New York, NY: Lippincott Williams & Wilkins; 2003:1914-1939.
45. Fleischmann C, Peto J, Chradle J, et al. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int J Cancer. 2004;118:554-558. (Pubitemid 38339646)
46. Renkonen ET, Nieminen P, Abdel-Rahman WM, et al. Adenomatous polyposis families that screen APC mutationYnegative by conventional methods are genetically heterogeneous. J Clin Oncol. 2005; 5651-5659.
47. Armstrong JG, Davies DR, Guy SP, et al. APC mutations in familial adenomatous polyposis families in the Northwest of England. Hum Mutat. 1997;10:376-380. (Pubitemid 27473298)
48. Russell AM, Zhang J, Luz J, et al. Prevalence of MYH germline mutations in Swiss APC mutationYnegative polyposis patients. Int J Cancer. 2006;118:1937-1940.
49. Aretz S, Uhlhaas S, Goergens H, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with attenuated or atypical phenotype. Int J Cancer. 2006;119:807-814. (Pubitemid 44051443)
50. Burt RW, Leppert MF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology. 2004;127:444-451. (Pubitemid 39091892)
51. Gallagher MC, Phillips RK, Bulow S. Surveillance and management of upper gastrointestinal disease in familial adenomatous polyposis. Fam Cancer. 2006;5:263-273. (Pubitemid 44453857)
52. Herraiz M, Barbesino G, FaquinW, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examination. Clin Gastroenterol Hepatol. 2007;5:367-373. (Pubitemid 46401518)
53. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:131-136.
54. Phillips RK,Wallace MH, Lynch PM, et al. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis on familial adenomatous polyposis. Gut. 2001;50:857-860. (Pubitemid 34539050)
55. Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev. 2006;15:312-314. (Pubitemid 43342180)
56. Doxey BW, Kuwada SK, Burt RW. Inherited polyposis syndromes: molecular mechanisms, clinicopathology, and genetic testing. Clin Gastroenterol Hepatol. 2005;3:633-641. (Pubitemid 40984722)
57. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MutYH-associated polyposis. Gastroenterology. 2009;137:1976-1985.
58. Webb EL, Rudd MF, Houlston RS. Colorectal cancer risk in monoallelic carriers of MYH variants. Am J Hum Genet. 2006;79:768-771. (Pubitemid 44452758)
59. Renkonen ET, Nieminen P, Abdel-Rahman WM, et al. Adenomatous polyposis families that screen APC mutation-negative by conventional methods are genetically heterogeneous. J Clin Oncol. 2005;33: 5651-5659.
60. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classical polyposis and with young-onset colorectal cancer without polyps. Gastroenterology. 2004;127:9-16. (Pubitemid 38962269)
61. Jo WS, Bandipalliam P, Shannon KM, et al. Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol. 2008;10:1022-1028.
62. Jones S, Emmerson P, Maynaard J, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:CYT:A mutations. Hum Mol Genet. 2002;11:2961-2967.
63. Kastrinos F, Syngal S. Recently identified colon cancer predispositions: MYH and MSH6 mutations. Semin Oncol. 2007;34:418-424. (Pubitemid 47503273)
64. Lubbe SJ, DiBernardo MC, Chandler IP, et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol. 2009;27:3975-3980.
65. Sieber O, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germline mutations in MYH. N Engl J Med. 2004;348:791-799.
66. Wagner A, Hendriks YMC, Meijers-Heijboer EJ, et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet. 2001;38:318-322. (Pubitemid 32433985)
67. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol. 2006;4: 408-415.
68. Van Lier MGF, Wagner A, Mathus-Vliegen MD, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:158-164.
69. Wirtzfeld DA, Petrelli NJ, Rodriguez-Bigas MA. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations. Ann Surg Oncol. 2001;8:319-327. (Pubitemid 32422857)
70. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in oncology: colorectal cancer screening. Available at: http:// www.nccn.org. Accessed August 1, 2011.
71. Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc. 2011;86:489-492.
72. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139:1927-1933.